Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
Graft loss including death · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.84 [0.67, 1.06]11 studies · 3476 participantsModerate